PPARG and neoplasm: Notwithstanding possible “off-target” effects[59, 60], most studies indicate that PPARγ agonists as a class have antitumor activity, andthus may have efficacy as a relatively nontoxic adjunct to chemotherapy andpossibly to radiation therapy through their ability to act as “tumor suppressorenhancers.”